This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
At ASH 2018, the CLL game-changer was the late-breaking abstract on the large phase 3 trial that compared the gold standard of FCR versus ibrutinib combined with rituximab (I+R).
I+R came out the “winner” in both overall survival (OS) and progression-free survival (PFS).
This should sound familiar.
Because it was the biggest CLL news at ASH 2018, we have focused on it in a number of commentaries, including this interview with Dr. Neil Kay from Mayo Clinic, Rochester, MN, one of the investigators who brings out some interesting points not covered elsewhere.
For my interview with the principal investigator, Dr. Shanafelt, see this.
This story was even picked up by CNN. For my review of the published article from the NEJM and the press coverage, read here.
Please enjoy my ASH 2018 interview with Dr. Kay on this important research.
This should change everything. That’s why we are pushing awareness.
We are all in this together.
Brian Koffman MDCM DCFP, DABFM, MS Ed
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc.